The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06057025
Recruitment Status : Not yet recruiting
First Posted : September 28, 2023
Last Update Posted : September 28, 2023
Sponsor:
Information provided by (Responsible Party):
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Safety, reactogenicity and immunogenicity study of the drug "Sputnik Lite" for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of adult volunteers.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety, Reactogenicity and Immunogenicity Study of the Drug "Sputnik Lite" for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Composition With Participation of Adult Volunteers.
Estimated Study Start Date : September 2023
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Healthy patients
Drug: Sputnik Light vector vaccine for the prevention of coronavirus infection caused by the SARS CoV-2 virus (with altered antigenic composition); A total of 50 people will be randomized and receive the study drug. A single intramuscular injection of the investigational medicinal product (IMP) will be performed.
 Biological: "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition
Single intramuscular injection of "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Occurrence of adverse events (AE) [ Time Frame: Within 28 days after administration of the drug ]
    Occurrence of adverse events (AE)

  2. Occurrence of serious adverse events (SAEs) [ Time Frame: Throughout Study completion, until December 2024 ]
    Occurrence of serious adverse events (SAEs)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

The study will include volunteers who meet all the specified criteria:

  1. Subject's written informed consent to participate in the study;
  2. Adult volunteer's men and women over 18 years old;
  3. A negative test result for COVID-19, determined by PCR or express method before the introduction of the investigational medicinal product (IMP).
  4. Consent to the use of effective methods of contraception during the entire period of participation in the study;
  5. A negative pregnancy test based on the results of a urine test at a screening visit (for women with preserved reproductive potential);
  6. Negative test for the presence of narcotic and psychostimulants in the urine at the screening visit;
  7. Negative alcohol content test at the screening visit;
  8. No contraindications to vaccination;
  9. Absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.

Exclusion Criteria:

Volunteers cannot be included in the study if there is at least one of the following criteria for non-inclusion:

  1. No signed informed consent to participate in the study;
  2. Therapy with steroids (with the exception of hormonal contraceptives and/or hormone replacement therapy) and / or immunoglobulins or other blood products that did not end 30 days before inclusion in the study;
  3. Therapy with any immunosuppressive drugs completed less than 3 months before inclusion in the study;
  4. Female subjects during pregnancy or lactation;
  5. Acute coronary syndrome or stroke suffered less than one year before inclusion in the study;
  6. Tuberculosis, chronic systemic infections according to anamnesis;
  7. Burdened allergic anamnesis (the presence in the anamnesis of information about anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the administration of immunobiological drugs, known allergic reactions to the components of the drug, exacerbation of allergic diseases on the day of inclusion in the study;
  8. The presence of neoplasms (ICD codes C00-D09) (according to the anamnesis);
  9. Splenectomy (according to the anamnesis);
  10. Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency - 6 months prior to inclusion in the study (according to the anamnesis);
  11. Subjects with an active form of the disease caused by human immunodeficiency virus, syphilis, hepatitis B and C (according to anamnesis);
  12. Anorexia, protein deficiency of any origin;
  13. Alcoholism and drug addiction (according to anamnesis);
  14. The subject's participation in any other interventional clinical trial (with the exception of rescreening in the current study) in the last 90 days;
  15. Extensive tattoos at the injection sites (deltoid muscle area), which do not allow to assess the local reaction to the introduction of investigational medicinal product (IMP);
  16. Any other condition of the subject of the study, which, in the opinion of the research doctor, may prevent the completion of the study in accordance with the protocol;
  17. Vaccination against COVID-19 or transmitted coronavirus infection COVID-19 less than 6 months before screening;
  18. Repeated administration of the Sputnik V vaccine, Sputnik Lite, or repeated administration of any other COVID-19 vaccine for more than three injections (Sputnik V vaccination plus Sputnik Lite revaccination);
  19. Inability to read in Russian; inability or unwillingness to understand the essence of the study;
  20. Any other conditions that limit the validity of obtaining informed consent or may affect the ability of the volunteer to participate in the study, affect the ability of the volunteer to participate in the study;
  21. Staff of research centers (chief researcher and members of the research team) directly involved in the research and their family members.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
ClinicalTrials.gov Identifier: NCT06057025    
Other Study ID Numbers: 14-Sputnik Lite / N-2023
First Posted: September 28, 2023    Key Record Dates
Last Update Posted: September 28, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases